Library
aglaia-oncology.comCrawled Oct 26, 2026
Product
1 page- Investments/investments
Press
6 pages- Archive/news/archive
- Genmab A/S to acquire Merus N.V. in US $ 8 billion all cash transaction/news/genmab-as-acquires-aglaia-portfolio-company-merus-nv-in-us-8-billion-all-cash-transaction
Genmab to acquire Merus, Expanding Late-Stage Pipeline in an all-cash transaction representing a transaction value of approximately USD 8.0 billion.
- MIMETAS and Yamaha Motor Sign Joint Marketing Agreement to Advance Automated Human Disease Model Applications for Drug Development/news/mimetas-and-yamaha-motor-sign-joint-marketing-agreement-to-advance-automated-human-disease-model-applications-for-drug-development
Strategic joint marketing agreement MIMETAS and Yamaha Motor.
- MIMETAS Contributes with Human Organ-on-Chip Data to IND Application by argenx/news/mimetas-contributes-with-human-organ-on-chip-data-to-ind-application-by-argenx
The research seamlessly aligns with the goals set forth by the 2022 FDA Modernization Act 2.0, emphasizing the use of in vitro models to investigate the safety and effectiveness of drugs.
Team
6 pages- Eric van der Putten/team/eric-van-der-putten
- Ernst Geutjes/team/ernst-geutjes
- Folkert van Cleef/team/folkert-van-cleef
- Karl Rothweiler/team/karl-rothweiler
About
3 pages- About Aglaia/about-aglaia
Through its Oncology Funds I and II, Aglaia has invested in 12 early stage companies, of which 6 were founded by Aglaia. Over the last 14 years, Aglaia has built an excellent reputation starting up biotech companies that focus on oncology drug development.
- ESG/esg
- Impact/impact
Life Science Impact Suite
Contact
1 page- Contact Aglaia Oncology Funds/contact
Contact Aglaia Oncology Funds, Berg en Bosch, Bilthoven
Homepage
1 page- Homepage/
Aglaia is an oncology specialist investor which selects and matures early-stage breakthrough inventions that have the potential to transform cancer prevention, diagnosis and therapy.
Privacy
1 page- Privacy policy/privacy
Privacy policy Aglaia
